The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Maximizing Tumor Immunity With Fractionated Radiation
Open accessAbstract
PURPOSE Technological advances have led to increased clinical use of higher sized fractions of radiation dose and higher total doses. How these modify the pathways involved in tumor cell death, normal tissue response, and signaling to the immune system has been inadequately explored. Here we ask how radiation dose and fraction size affect anti-tumor immunity, the suppression thereof and how this might relate to tumor control. MATERIALS and METHODS Mice bearing B16-OVA murine melanoma were treated with up to 15Gy radiation given in various sized fractions and tumor growth followed. The tumor-specific immune response in the spleen was assessed by IFNγ-Enzyme-Linked Immuno-Spot (ELISPOT) assay with ovalbumin (OVA) as the surrogate tumor antigen and the contribution of regulatory T cells (Tregs) determined by the proportion of CD4+CD25hiFoxp3+ T cells. RESULTS After single doses, tumor control increased with the size of radiation dose, as did the number of tumor-reactive T cells. This was offset at the highest dose by an increase in Treg representation. Fractionated treatment with medium-size radiation doses of 7.5Gy/fraction gave the best tumor control and tumor immunity while maintaining low Treg numbers. CONCLUSIONS Radiation can be an immune adjuvant but the response varies with the size of dose per fraction. The ultimate challenge is to optimally integrate cancer immunotherapy into radiation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity
Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3132 · Cited by 485
Radiation Enhances Regulatory T Cell Representation
Kachikwu, E. L., Iwamoto, K. S., Liao, Y.-P., DeMarco, J. J., Agazaryan, N., Economou, J. S., McBride, W. H., & Schaue, D. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.034 · Cited by 429
Self-citationA Sense of Danger from Radiation1
McBride, W. H., Chiang, C.-S., Olson, J. L., Wang, C.-C., Hong, J.-H., Pajonk, F., Dougherty, G. J., Iwamoto, K. S., Pervan, M., & Liao, Y.-P. (2004) · Radiation Research · doi:10.1667/rr3196 · Cited by 323
Self-citation
Cited by
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Theelen, W. S. M. E., Peulen, H. M. U., Lalezari, F., van der Noort, V., de Vries, J. F., Aerts, J. G. J. V., Dumoulin, D. W., Bahce, I., Niemeijer, A.-L. N., de Langen, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1478 · Cited by 1,002
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Opportunities and challenges of radiotherapy for treating cancer
Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784
Self-citationRadiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Sharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
Luke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2229 · Cited by 588
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 509
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H., & Yu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0647-8 · Cited by 447
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
Gupta, A., Probst, H. C., Vuong, V., Landshammer, A., Muth, S., Yagita, H., Schwendener, R., Pruschy, M., Knuth, A., & van den Broek, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200563 · Cited by 446
Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
Hellevik, T., & Martinez-Zubiaurre, I. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00001 · Cited by 442
Abscopal effects of radiation therapy: A clinical review for the radiobiologist
Siva, S., MacManus, M. P., Martin, R. F., & Martin, O. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2013.09.018 · Cited by 441
Dudek, A. M., Martin, S., Garg, A. D., & Agostinis, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00438 · Cited by 399
Cytokines in Radiobiological Responses: A Review
Schaue, D., Kachikwu, E. L., & McBride, W. H. (2012) · Radiation Research · doi:10.1667/rr3031.1 · Cited by 399
Self-citationImmunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Ni, K., Lan, G., Chan, C., Quigley, B., Lu, K., Aung, T., Guo, N., La Riviere, P., Weichselbaum, R. R., & Lin, W. (2018) · Nature Communications · doi:10.1038/s41467-018-04703-w · Cited by 336
Radiation as an immunological adjuvant: current evidence on dose and fractionation
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 332
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 313
Parikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y., Raabe, M., Thel, H., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 294
Radiation and immunotherapy: a synergistic combination
Kalbasi, A., June, C. H., Haas, N., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 284
The Effect of Radiation on the Immune Response to Cancers
Park, B., Yee, C., & Lee, K.-M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15010927 · Cited by 272
Butterfield, L. H. (2015) · BMJ · doi:10.1136/bmj.h988 · Cited by 272
Verstegen, N. E., Oosterhuis, J. W. A., Palma, D. A., Rodrigues, G., Lagerwaard, F. J., van der Elst, A., Mollema, R., van Tets, W. F., Warner, A., Joosten, J. J. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt026 · Cited by 267
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 264
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Adkins, I., Fucikova, J., Garg, A. D., Agostinis, P., & Špíšek, R. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968434 · Cited by 200
Metadata
- Authors
- Schaue, D., Ratikan, J. A., Iwamoto, K. S., & McBride, W. H.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 83
- Issue
- 4
- Pages
- 1306-1310
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2001816519
- Cited by
- 567
- References
- 17
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.